Biotech innovations - Company finances
|
EUR
|
2024
From: 2024-06-03
To: 2024-12-31
|
2025
From: 2024-07-01
To: 2025-12-31
|
|---|---|---|
|
Financial data
|
||
| Sales revenue | 9,652 | 543,755 |
| Profit before tax | -1,358 | 149,902 |
| Net profit | -1,358 | 126,135 |
| Equity | 642 | 126,777 |
| Liabilities | 5,141 | 76,363 |
| Non-current assets | 0 | 0 |
| Current assets | 5,783 | 203,140 |
| Total assets | 5,783 | 203,140 |
|
Taxes paid
|
||
| STI taxes | 245 | 563 |
|
Financial indicators
|
||
| Revenue change y/y | - | +5533.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -23.5% | 62.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -211.5% | 99.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -14.1% | 23.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -14.1% | 27.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 8.0 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 292,798 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biotech innovations - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-07-19 | 2026-07-19 | 1508.46 |
| 2026-07-16 | 2026-07-17 | 1508.46 |
| 2025-03-01 | 2025-03-31 | 72.45 |
| 2025-02-11 | 2025-02-28 | 136.95 |
| 2025-02-10 | 2025-02-10 | 64.50 |
| 2025-02-01 | 2025-02-09 | 136.95 |
| 2025-01-02 | 2025-01-31 | 64.50 |
| 2024-12-03 | 2024-12-31 | 193.50 |
| 2024-11-04 | 2024-12-02 | 129.00 |
| 2024-10-01 | 2024-11-03 | 64.50 |
| 2024-09-03 | 2024-09-30 | 129.00 |
| 2024-08-01 | 2024-09-02 | 64.50 |
Biotech innovations - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-08-26 | 2026-08-26 | 1092.42 |
| 2026-08-25 | 2026-08-25 | 41582.42 |
| 2026-08-23 | 2026-08-24 | 41549.71 |
| 2026-08-20 | 2026-08-22 | 57611.55 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biotech innovations, MB (code 306815954) is a Lithuanian small partnership engaged in the wholesale of other chemical products. In the latest financial year, 2025, revenue rose to €543.8K from €9.7K in 2024, reflecting a sharp expansion from a very small prior-year base. Net profit improved from a €1.4K loss in 2024 to €126.1K in 2025, and the profit margin reached 23.2%. The business also reported strong capital efficiency, with return on equity at 99.5% and return on assets at 62.1%. Balance sheet strength improved materially: total assets stood at €203.1K, equity at €126.8K, and liabilities at €76.4K, resulting in an equity ratio of 62.4% and debt-to-equity of 0.60. Asset turnover was 2.68x, indicating solid use of the asset base to generate sales. Revenue per employee was €543.8K and profit per employee was €126.1K, pointing to high productivity in 2025.